Create an Account

Digital Flashcards: HER2+ mBC

Digital Flashcards: HER2+ mBC

Digital Flashcards: HER2+ mBC
RestartResume

    Put yourself to the test with this interactive Digital Flashcard activity. Are you up to date on current and emerging standards of care in HER2+ mBC?

    Available credits: 0.25

    Time to complete: 15 minutes

    Released:

    Valid until:

    Take Post-Test

    If you’ve already completed the activity.

    • Overview

      HER2 is overexpressed and/or amplified in about 20% of breast cancers and signals aggressive tumor behavior. However, it also opens the door for targeted therapeutic options, and patients with advanced or metastatic disease are now seeing greatly improved prognoses with the emergence of new anti-HER2 therapies. But with more options comes more complexity.

      In this interactive Digital Flashcards activity, you will work through 3 different patient cases of HER2-positive metastatic breast cancer. Can you choose the best treatment options? These patient scenarios will test your knowledge and experiences—are you up for the challenge?

      Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about this data, please visit here. 

    • Disclosure of Conflicts of Interest

      In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

      Sara A. Hurvitz, MD, FACP
      Professor of Medicine
      Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology
      David Geffen School of Medicine, UCLA
      Santa Monica, CA 

      Contracted Research: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, Puma, Radius, Samumed, Sanofi, Seattle Genetics, Zymeworks
      Ownership Interest: NKMax; (spouse): ROMTech, Ideal Implant

       Reviewers/Content Planners/Authors:

      • Jorge Bacigalupo has nothing to disclose.
      • Ann Early has nothing to disclose.
      • Nicole Fox, DNP, MSN-Ed, RN, OCN, has nothing to disclose.
      • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
      • Anna Trentini has nothing to disclose.

    • Learning Objective

      After participating in this educational activity, participants should be better able to:

      • Assess your improvement in selecting optimal treatment strategies based on individual patient characteristics in the HER2-positive mBC setting

    • Target Audience

      This activity is designed to meet the educational needs of community medical oncologists, academic medical oncologists, and pathologists.

    • Accreditation and Credit Designation Statements

      In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

      Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Provider(s)/Educational Partner(s)

      Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

      Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

    • Commercial Support

      This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, and Seagen.

    • Disclaimer

      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

      Reproduction Prohibited
      Reproduction of this material is not permitted without written permission from the copyright owner.

    • System Requirements

      Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

    Related

    Facebook Comments

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We’re glad to see you’re enjoying Prova Education…
      but how about a more personalized experience?

      Register for free
      You are now leaving Prova Education and going to a site run by another organization.

      Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.